Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Long-term Outcome After Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
Abstract: Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged
Allogeneic Stem Cell Transplantation Using HLA-matched Donors for Acute Myeloid Leukemia with Deletion 5q Or Monosomy 5
Abstract: Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia (AML) is a common high-risk feature that is referred to allogeneic stem cell transplantation. However, -5/5q- is frequently associated with other high-risk cytogenetic aberrations such as complex karyotype, monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (17p)), the significance of which is unknown. In order to address this question, we studied adult patients with AML harboring -5/5q- having their first allogeneic transplantation between 2000 and 2015. Five hundred and one patients with -5/5q- have been analyzed. Three hundred and thirty-eight patients (67%) were in first remission and 142 (28%) had an act...
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Abstract: The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P
Recent Advances and Future Directions in Bone Marrow Transplantation
Siegmund J. Baum It has become a tradition to commence advocated by Leonard Cole) (3). important meetings of this society with At about the same time, Alpen and reminiscence and nostalgia. Bone marrow Baum (4), using a larger mammal, the dog, transplantation, which has a history of only demonstrated that injecting autologous marrow 30 to 40 years, permits this process, since post irradiation would protect lethally some of the early investigators are still with irradiated animals (see Table). Certainly, us. For example, over the past 15 years, we protection was obtained from the cellular have had three symposia in honor of Egon constituents of the bone marrow. Lorenz. As we all know, the team of Lorenz, We undertook to test on dogs the Uphoff and Congdon was involved in the first hypothesis of Gengozian and Makinodum (5) that successful transplantation of syngeneic and increasing the radiation dose will increase allogeneic bone marrow into irradiated immunologic tolerance for allogeneic implants.
Acta Haematologica
None
Cancer FAX Directory
None
